Differential effects of N-acetylcysteine on nitroglycerin- and nicorandil-induced vasodilation in human coronary circulation

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 1, 1998, Pages 21-28

  Nishikawa, Yasuhiro ^a,c   Kanki, Hideaki ^b   Ogawa, Satoshi ^b  

^a TOKYO DENTAL COLLEGE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Coronary vasodilation; K+ channel; Nicorandil; Nitroglycerin; Quantitative coronary angiography

Indexed keywords

ACETYLCYSTEINE; GLYCERYL TRINITRATE; NICORANDIL; THIOL GROUP;

ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; FEMALE; HUMAN; INTRACORONARY INFUSION; MALE; PRIORITY JOURNAL; VASODILATATION;

ACETYLCYSTEINE; CORONARY CIRCULATION; CORONARY DISEASE; CORONARY VESSELS; FEMALE; FREE RADICAL SCAVENGERS; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; NIACINAMIDE; NICORANDIL; NITROGLYCERIN; VASODILATION; VASODILATOR AGENTS;

EID: 0031777156     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199807000-00004     Document Type: Article

References (39)

1. Parker JO. Nitrate therapy in stable angina pectoris. N Engl J Med 1987;316:1635-42.
2. Leier CV, Huss P, Magorien RD, Unverferth DV. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation 1983;67:817-22.
3. Münzel T, Holtz J, Mülsch A, Stewart DJ, Bassenge E. Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo but not tolerance-independent interactions exist
4. Winniford MD, Kennedy PL, Wells PJ, Hills LD. Potentiation of nitroglycerin-induced coronary dilatation by N-acetylcysteine. Circulation 1986;73:138-42.
5. Parker JO, Farrell B, Lahey KA, Rose BF. Nitrate tolerance: The lack of effect of N-acetylcysteine. Circulation 1987;76:572-6.
6. Henry PJ, Horowitz JD, Louis WJ. Determination of in vitro nitroglycerin tolerance induction and reversal: influence of dose regimen, nitrate-free period, and sulfhydryl supplementation. J Cardiovasc Pharmacol 1989;14:31-7.
7. Henry PJ, Horowitz JD, Louis WJ. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: of dose regimen, nitrate-free period, and sulfhydryl supplementation. J Cardiovasc Pharmacol 1989;14:31-7.
8. Furukawa K, Itoh T, Kajiwara M, et al. Vasodilating actions of 2-nicotinamidethyl nitrate on porcine and guinea-pig coronary arteries. J Pharmacol Exp Ther 1981;218:233-44.
9. Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther 1990;4:1075-88.
10. Henry PJ, Horowitz JD, Louis WJ. Nitrate tolerance induced by nicorandil or nitroglycerin is associated with minimal loss of nicorandil vasodilator activity. J Cardiovasc Pharmacol 1990;15: 365-70.
11. Taira N. Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview. J Cardiovasc Pharmacol 1987;10(suppl 8):S1-9.
12. Hashimoto K, Kinoshita M, Ohbayashi Y. Coronary effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs. Cardiovasc Drugs Ther 1991;5:131-8.
13. Hamilton TC, Weston AH. Cromakalim, nicorandil, and pinacidil: novel drugs which open potassium channels in smooth muscle. Gen Pharmacol 1989;20:1-9.
14. Yoneyama F, Satoh K, Taira N. Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism. Cardiovasc Drugs Ther 1990;4:1119-26.
15. Satoh K, Yamada H, Taira N. Differential antagonism by glibenclamide of the relaxant effects of cromakalim, pinacidil, and nicorandil in canine large coronary arteries. Naunyn Schmiedebergs Arch Pharmacol 1991;343:76-82.
16. Imagawa J, Akima M, Nabata H, Taira N. Spasmolytic action of nicorandil in canine conductive arteries in vivo is not modified by glibenclamide. J Cardiovasc Pharmacol 1992;19:108-14.
17. Berdeaux A, Drieu la Rochelle C, Richard V, Giudicelli JF. Differential effects of nitrovasodilators, potassium channel openers and nicorandil on large and small coronary arteries in conscious dogs. J Cardiovasc Pharmacol 1992;20(suppl 3):S17-21.
18. Tschudi M, Richard V, Buhler ER, Luscher TF. Importance of endothelium-derived nitric oxide in intramyocardial porcine coronary arteries. Am J Physiol 1990;260:H13-20.
19. Crossman DC, Larkin SW, Fuller RW, Davies GJ, Maseri A. Substance P dilates epicardial coronary arteries and increases coronary blood flow in humans. Circulation 1989;80:475-84.
20. Aizawa T, Ogasawara K, Kato K. Effects of nicorandil on coronary circulation in patients with ischemic heart disease: comparison with nitroglycerin. J Cardiovasc Pharmacol 1987;10(suppl 8):S123-9.
21. Lawson DL, Nichols WW, Mehta P, Mehta JL. captopril-induced reversal of nitroglycerin tolerance: role of sulfhydryl group vs. ACE-inhihitory activity. J Cardiovasc Pharmacol 1991;17:411-8.
22. Abdollah A, Moffat JA, Armstrong PW. N-Acetylcysteine does not modify nitroglycerin-induced tolerance in canine vascular rings. J Cardiovasc Pharmacol 1987;9:445-50.
23. Boesgaard S, Iversen HK, Wroblewski H, et al. Altered peripheral vasodilator profile of nitroglycerin during long-term infusion of N-acetylcysteine. J Am Coll Cardiol 1994;23:163-9.
24. Iversen HK. N-Acetylcysteine enhances nitroglycerin-induced headache and cranial arterial responses. Clin Pharmacol Ther 1992;52:125-33.
25. Yasue H, Matsuyama K, Maysuyama K, Okumura K, Morikami Y, Ogawa H. Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment. Circulation 1990;81:482-90.
26. Yanagisawa T, Taira N. Effects of 2-nicotinamidethyl nitrate (SG75) on the membrane potential of left trial muscle fibers of the dog: increase in potassium conductance. Naunyn Schmiedebergs Arch Pharmacol 1980;312:69-76.
27. Flaherty JT. Nitrate tolerance: a review of the evidence. Drug 1989;37:523-50.
28. Suryapranata H, MacLeod D. Nicorandil and cardiovascular performance in patients with coronary heart disease. J Cardiovasc Pharmacol 1992;20(suppl 3):S45-92.
29. Kobayashi K, Hakuta T. Effects of nicorandil on coronary hemodynamics in ischemic heart disease: comparison with nitroglycerin, nifedipine, and propranolol. J Cardiovasc Pharmacol 1987; 8:S109-15.
30. Murakami M, Takenaka Y, Matsubara H, Hasegawa S, Nakamura N. Effects of intravenous injection of nicorandil on systemic and coronary hemodynamics in patients with old myocardial infarction (OMI): a comparative study with nifedipine and ISDN [Abstract]. Eur Heart J 1989;10(suppl):426.
31. + channel openers: moving towards cardioprotection via strengthening of a natural mechanism. Trends Pharmacol Sci 1992;13:269-72.
32. Galie N, Guarnieri C, Ussia GP, et al. Limitation of myocardial infarct size by nicorandil after sustained ischemia in pigs. J Cardiovasc Pharmacol 1995;26:477-84.
33. Auchampach JA, Gross GJ. Anti-ischemic actions of potassium channel openers in experimental myocardial ischemia/reperfusion injury in dogs. Eur Heart J 1993;14:10-5.
34. Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells on beads. Hypertension 1991;17:187-93.
35. Kelm M, Feelisch M, Deussen A, Strauer BE, Schrader J. Release of endothelium derived nitric oxide in relation to pressure and flow. Cardiovasc Res 1991;25:831-6.
36. Fung HL, Chong S, Kowaluk E, Hough K, Kakemi M. Mechanisms for the pharmacologic interaction of organic nitrates with thiols: existence of an extracellular pathway for the reversal of nitrate vascular tolerance by N-acetylcysteine. J Pharmacol Exp Ther 1988;245:524-30.
37. Feelisch M, Noak E. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987;139:19-30.
38. Feldman RL, Marx JD, Pepine CJ, Conti DR. Analysis of coronary responses to various doses of intracoronary nitroglycerin. Circulation 1982;66:321-7.
39. Hongo M, Takenaka H, Uchikawa S, et al. Coronary microvascular response to intracoronary administration of nicorandil. Am J Cardial 1995;75:246-50.